DermTech Revenue and Competitors

Claim your profile



Growjo Ranking



Estimated Revenue & Valuation

  • DermTech's estimated annual revenue is currently $44.6M per year.(i)
  • DermTech's estimated revenue per employee is $130,526
  • DermTech's total funding is $259.9M.

Employee Data

  • DermTech has 342 Employees.(i)
  • DermTech grew their employee count by 62% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

DermTech is the global leader in molecular dermatology, bringing precision medicine to the diagnosis and treatment of skin disease. We market and develop products that facilitate the early detection of skin cancers, assess inflammatory diseases, and customize drug treatments. DermTech analyzes skin biopsy samples collected non-invasively using an adhesive patch rather than a scalpel. Our mission is to transform dermatology by delivering highly accurate and objective information to the clinician to improve care and reduce costs and to pharma partners to support the development of targeted therapeutics. DermTech's Pigmented Lesion Assay (PLA) provides physicians with a non-invasive option to identify clinically atypical pigmented lesions (or moles) at high risk for melanoma. Using an adhesive patch rather than a scalpel, DermTech provides highly accurate, objective information to the physician to improve patient care and comfort through advanced molecular pathology gene expression. The PLA is intended for use on pigmented skin lesions, which are clinically suspicious for melanoma. These lesions may meet one or more ABCDE criteria. The diagnosis of early stage melanoma is inaccurate by visual assessment and histopathologic slide review. The false negative diagnosis for melanoma in-situ/Stage 1 a melanoma was found to be 35% in a recent large scale study of pathologists in the US. By comparison, the PLA has a negative predictive value of 99% and significantly reduces the number needed to biopsy.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





DermTech News

2022-04-20 - DermTech to Showcase DermTech Stratum, an Expanded ...

DermTech to Showcase DermTech Stratum, an Expanded Translational Medicine Service Offering, at San Diego's Inaugural 'Innovation Day' Event.

2022-03-30 - DermTech - Taking A Second Look At The Growth Thesis

As a refresher, DermTech, Inc. is a molecular diagnostic company that develops and markets non-invasive tests to diagnose skin conditions and...

2022-03-22 - DermTech Announces Inducement Grants Under Nasdaq ...

DermTech's mission is to transform dermatology with our non-invasive skin genomics platform, to democratize access to high quality dermatology...

2021-11-09 - Slone Partners Places L’Oréal USA Consumer Products Division President Nathalie Gerschtein Keraudy on Board of Directors at DermTech

“Her extensive strategic and operational experience and innovative spirit will be valuable additions to the DermTech Board of Directors and great support for the company's leadership team,” said Slone Partners President Tara Kochis. SOUTH RIDING, Va. (PRWEB) November 09, 2021 Slone Partners, a ...

2017-11-01 - DermTech Raises $10M In Series C Funding

La Jolla-based molecular dermatology startup DermTech announced today that it has raised $10M in its Series C funding round, part of an ongoing $15M financing effort by the company. The startup, which is developing precision medicine technology for the diagnosis and treatment of skin cancers, in ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding